|
|
 |
|
Viewing report
|
|
|
|
Breast Cancer Vaccines and Therapeutic Antibodies: Pipeline - 2011
BioPharm Reports (VennBio Ltd.), Feb 2011, Pages: 95
The breast cancer immunotherapy pipeline is showing rapid development. This report presents findings on more than 30 candidate therapies, including 22 therapeutic vaccines and 11 antibodies. Of the 22 vaccines in development, 7 (32%) are at clinical phases II – III.
Drugs used to treat breast cancer fall into three main groups: hormonal blockers, chemotherapeutic agents and targeted antibodies. While these provide important treatment options for patients, their limitations (drug resistance, poor efficacy and side effects) have focused efforts on developing safer and more effective targeted therapies. Currently, the greatest growth in this field is in the development of breast cancer immunotherapies; therapeutic vaccines and antibodies.
This report presents a comprehensive review of the breast cancer immunotherapy pipeline, covering new candidate vaccines and antibodies. Currently, there are more than 20 candidate breast cancer vaccines in the pipeline. These include selective candidates, developed to target breast cancer and others, that are being evaluated against a number of cancer types, including breast cancer. This report also covers current developments on 11 antibodies, some of which are new molecules developed to selectively target breast cancer and others, that are being evaluated for a number of cancers, including breast cancer.
The development of candidate vaccines is seeing significant innovation, as companies establish novel biological strategies to stimulate the immune system to target antigens associated with breast cancer. Of the 22 candidate vaccines in development, 7 (32%) are at clinical phases II – III. This report also includes a technical overview of each of the candidate therapeutic vaccines and antibodies discussed.
The candidates vaccines and antibodies identified in this report target 17 different cancer antigens or (antibody) drug targets and these developments are being taken forward by 30 different companies. Of these, 23 (77%) are small and medium-sized organisations or groups, and seven are major multinational pharmaceutical companies. Of these candidates, two, three, one, eight, seven, seven and six are Approved or at Phase III, Phase II/III, Phase II, Phase I/II, Phase I or at the preclinical stage, respectively.
This report provides a comprehensive review on the breast cancer immunotherapy pipeline and presents summary clinical findings (pre-clinical to Phase III) on the candidates presented, including a discussion of current biological strategies to develop new immunotherapies. These developments are creating new partnering opportunities in this field.
|
|
|
|
